Repatha (Evolocumab) Monitoring for Adults 65 and Older

Why Geriatric Monitoring Differs from Standard Evolocumab Follow-Up

Adults over 65 process evolocumab through the same receptor-mediated endocytosis as younger patients, yet several age-related changes alter how clinicians should track outcomes. Reduced hepatic blood flow, declining renal clearance, shifting body composition, and higher baseline polypharmacy all affect how the drug behaves in practice.

In the FOURIER trial (N=27,564), approximately 40% of participants were 65 or older. A prespecified age-subgroup analysis found consistent LDL-C lowering across age categories, with a 15% relative reduction in the composite cardiovascular endpoint [1]. The absolute benefit was numerically larger in older participants because their baseline event rate was higher. But older adults also carried higher rates of comorbid chronic kidney disease (CKD), diabetes, and concurrent use of five or more medications.

The 2018 AHA/ACC Multisociety Cholesterol Guideline explicitly notes that clinicians should weigh frailty, life expectancy, and patient preferences when intensifying lipid-lowering therapy after age 75 [2]. That recommendation applies directly to PCSK9 inhibitor initiation and ongoing monitoring. A 78-year-old with stable angina, an eGFR of 38, and six concurrent medications is not the same clinical scenario as a 52-year-old post-MI patient on two drugs.

Lipid Panel Schedule: When and How Often to Check

Draw a fasting lipid panel 4 to 12 weeks after the first injection. If LDL-C drops below the target (typically <70 mg/dL for established ASCVD, or <55 mg/dL for very high-risk patients per 2019 ESC/EAS guidelines [3]), transition to every-6-month monitoring for the first year, then annually if values remain stable.

Three situations call for more frequent draws in geriatric patients. First, any change in statin dose or type. Adding, removing, or adjusting a statin alters the LDL-C equilibrium, and the new steady state takes 4 to 6 weeks to establish. Second, acute illness or hospitalization. Inflammatory states (pneumonia, hip fracture, post-surgical recovery) transiently lower LDL-C, masking medication effects. Recheck 6 to 8 weeks after discharge. Third, new medications that affect lipid metabolism, including corticosteroids, thiazides, or certain antiretrovirals.

The target LDL-C floor also warrants attention. FOURIER showed that LDL-C levels below 20 mg/dL were achieved by roughly 10% of evolocumab-treated patients, and no excess adverse events appeared in this subgroup over 2.2 years [1]. The EBBINGHAUS cognitive substudy (N=1,974) found no difference in cognitive function between evolocumab and placebo groups [4], though follow-up was limited. For patients over 75, the absence of long-term data below this threshold means clinicians should document the LDL-C nadir and discuss it with the patient at each visit.

Renal Function Monitoring

Evolocumab itself is not nephrotoxic. It does not undergo renal clearance. Still, kidney function monitoring is necessary for two reasons. It shapes overall cardiovascular risk, which determines whether PCSK9 inhibitor therapy remains appropriate. And it affects the tolerability of concurrent statins, ezetimibe, and other medications in the patient's regimen.

Check serum creatinine and eGFR at baseline. Repeat at 6 months after initiation, then annually. If eGFR is <45 mL/min/1.73 m², increase frequency to every 6 months. A 2020 post-hoc analysis of FOURIER demonstrated that patients with CKD stage 3 (eGFR 30 to 59) experienced a consistent relative risk reduction with evolocumab, but their absolute risk reduction was approximately twice that of patients with normal kidney function because their baseline event rate was higher [5].

If eGFR declines below 30 mL/min/1.73 m² during treatment, the drug itself does not need dose adjustment. But the entire lipid-lowering regimen should be reassessed. High-intensity statins may need reduction (rosuvastatin from 40 mg to 20 mg, for example). Ezetimibe clearance is unaffected by renal impairment, so it can remain. The clinical question becomes whether the evolocumab is still providing incremental benefit beyond the statin-ezetimibe combination that the patient can tolerate.

Hepatic Enzyme Surveillance

Baseline ALT and AST are standard before any lipid-lowering intensification. Repeat at 12 weeks. If values remain within 3 times the upper limit of normal, routine annual monitoring is sufficient.

Geriatric patients deserve closer attention here because of polypharmacy. Acetaminophen (even at therapeutic doses with regular use), amiodarone, methotrexate, and certain antibiotics all stress hepatic pathways. A new transaminase elevation in an older adult on evolocumab is far more likely to reflect a drug interaction with something else in the regimen than a direct effect of the PCSK9 inhibitor.

The Repatha prescribing information (FDA label) does not list hepatotoxicity as a warning [6]. Pooled safety data across the PROFICIO program (over 6,000 patients receiving evolocumab) showed no significant difference in hepatic adverse events versus placebo [7]. This does not mean liver monitoring is optional. It means the purpose of monitoring is to detect interactions and background liver disease progression, not evolocumab-specific toxicity.

Cognitive Function Assessment

This is the monitoring domain that generates the most clinician questions. Short answer: structured cognitive screening is recommended at baseline and annually for patients over 75 on any aggressive lipid-lowering therapy. The concern is theoretical (cholesterol is a component of myelin), and current data do not support a causal link between very low LDL-C and cognitive decline.

The EBBINGHAUS trial, a cognitive substudy within FOURIER, used the Cambridge Neuropsychological Test Automated Battery (CANTAB) to assess executive function, working memory, and processing speed over a median of 19 months. No difference emerged between evolocumab and placebo groups, including in participants who achieved LDL-C <25 mg/dL [4].

However, 19 months is not 10 years, and EBBINGHAUS enrolled patients with a mean age of 63. Extrapolating those results to an 82-year-old with mild cognitive impairment at baseline requires caution. The 2018 AHA/ACC guideline recommends a clinician-patient discussion about the unknown long-term cognitive effects of very low LDL-C in adults over 75 [2].

Use a validated screening tool. The Montreal Cognitive Assessment (MoCA) takes about 10 minutes and detects mild impairment more sensitively than the Mini-Mental State Examination. Document the score. If there is a decline of 3 or more points from baseline over 12 months, evaluate for other causes (B12 deficiency, hypothyroidism, medication side effects from anticholinergics or benzodiazepines) before attributing the change to lipid-lowering therapy.

Injection-Site and Adherence Monitoring

Evolocumab is a subcutaneous injection, either via prefilled syringe or autoinjector. In older adults, injection-site monitoring requires deliberate attention because of three factors: skin thinning, anticoagulant use, and manual dexterity.

Check injection sites at every clinic visit. Rotate between abdomen, thigh, and upper arm. Persistent nodules lasting more than 7 days, expanding ecchymosis (particularly in patients on warfarin, apixaban, or rivarelbaban), or injection-site pain that discourages adherence all warrant intervention. Switching from the autoinjector to the prefilled syringe (or vice versa) can resolve dexterity-related issues. A caregiver or visiting nurse can administer the injection if self-injection becomes impractical.

Adherence tracking matters more in geriatric patients on the every-2-week regimen. A 2019 real-world analysis published in JAMA Cardiology found that only 55% of patients prescribed PCSK9 inhibitors maintained a proportion of days covered (PDC) above 80% at 12 months [8]. Older adults with cognitive impairment or complex medication schedules are at higher risk for missed doses. The once-monthly 420 mg option can improve adherence by reducing injection frequency. Ask about missed doses at every follow-up.

Polypharmacy Review and Drug Interactions

Evolocumab has no known cytochrome P450 interactions. It does not affect the metabolism of statins, ezetimibe, warfarin, or antihypertensives. This is a genuine clinical advantage in older adults taking 8 to 12 medications.

The monitoring task here is not about evolocumab interactions. It is about using the PCSK9 inhibitor visit as an opportunity to review the entire medication list. The American Geriatrics Society Beers Criteria (2023 update) identifies dozens of potentially inappropriate medications in older adults [9]. Patients seen in a lipid clinic for PCSK9 inhibitor follow-up may not receive regular geriatric pharmacy review elsewhere.

At minimum, check for these high-risk combinations at each evolocumab follow-up: statin plus fibrate (gemfibrozil specifically increases myopathy risk), triple antithrombotic therapy (dual antiplatelet plus anticoagulant), concurrent use of two or more drugs that prolong QTc, and anticholinergic burden score above 3. Document any changes or recommendations in the visit note.

When to Consider Deprescribing Evolocumab

Not every 65-year-old who starts Repatha should remain on it indefinitely. The benefit of PCSK9 inhibition depends on residual life expectancy, functional status, and competing risks. A framework for annual reassessment includes four criteria.

Life expectancy. If estimated survival drops below 2 to 3 years due to advanced malignancy, end-stage organ disease, or severe dementia, the 15% relative MACE reduction observed in FOURIER is unlikely to translate into meaningful clinical benefit within that time horizon. The number needed to treat (NNT) in FOURIER was 67 over 2.2 years for the primary composite endpoint [1]. In patients with limited life expectancy, that NNT may exceed the patient's remaining time.

Functional status. A patient who has transitioned to comfort-focused care, or who is no longer ambulatory, may not benefit from aggressive LDL-C lowering. The STOPP/START criteria (version 3) recommend deprescribing statins when life expectancy is <3 years [10]. While PCSK9 inhibitors are not yet included in these criteria, the same logic applies.

Patient preference. Some older adults express a clear preference to reduce their injection burden or pill count. Documenting this preference and acting on it is appropriate shared decision-making, not therapeutic nihilism.

Cost and access. Evolocumab carries a list price near $5,850 per year in the United States. Even with manufacturer copay programs, Medicare Part D coverage gaps can create out-of-pocket exposure. If cost affects adherence, a partially adherent PCSK9 inhibitor regimen is worse than a fully adherent high-intensity statin plus ezetimibe combination. The 2022 ACC Expert Consensus Decision Pathway for nonstatin therapies emphasizes maximizing statin and ezetimibe before adding a PCSK9 inhibitor, and this sequencing should be re-verified at annual review [11].

Building a Geriatric Evolocumab Monitoring Calendar

A practical monitoring schedule for a 70-year-old starting evolocumab with established ASCVD, CKD stage 3a, and five concurrent medications looks like this.

Baseline (week 0): Fasting lipid panel, comprehensive metabolic panel (including creatinine, eGFR, ALT, AST), MoCA or equivalent cognitive screen, injection training with return demonstration, medication reconciliation, falls risk assessment.

Week 4 to 12: Fasting lipid panel. Confirm LDL-C has dropped at least 50% from baseline. Assess injection-site tolerance and adherence.

Month 6: Repeat lipid panel, creatinine/eGFR, ALT/AST. Review medication list. Screen for new-onset myalgia or muscle weakness (which could reflect statin interaction, not evolocumab).

Month 12 and annually thereafter: Full lipid panel, renal function, hepatic enzymes, cognitive screening (MoCA), injection-site exam, adherence assessment, polypharmacy review, deprescribing evaluation. Reassess whether the patient still meets criteria for PCSK9 inhibitor therapy based on current guidelines, functional status, and goals of care.

For patients over 80 or with eGFR <30, consider adding a 6-month mid-cycle check that includes renal function and a brief cognitive assessment even if the annual screen was normal.

The evolocumab visit is both a lipid management check and a geriatric care opportunity. Treat it accordingly.